The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
MELBOURNE, Australia, June 25, 2026 /PRNewswire/ -- Bizcap has claimed the top ranking as Australia's Best Workplace™ in Finance and Insurance for 2026, awarded...
MELBOURNE, Australia, June 25, 2026 /PRNewswire/ -- Bizcap has claimed the top ranking as Australia's Best Workplace™ in Finance and Insurance for 2026, awarded...
BEIJING, June 25, 2026 /PRNewswire/ -- The "Chain Expo Launchpad" of the 4th China International Supply Chain Promotion Expo (Chain Expo) officially opened on June...
BEIJING, June 25, 2026 /PRNewswire/ -- The "Chain Expo Launchpad" of the 4th China International Supply Chain Promotion Expo (Chain Expo) officially opened on June...
SYDNEY, June 25, 2026 /PRNewswire/ -- Manhattan Associates Inc. (Nasdaq: MANH), the global leader in native AI-empowered supply chain commerce solutions, today announced a...
SYDNEY, June 25, 2026 /PRNewswire/ -- Manhattan Associates Inc. (Nasdaq: MANH), the global leader in native AI-empowered supply chain commerce solutions, today announced a...
